RxDoctor Payments Data

David Sandercock, DO

Family Medicine · San Antonio, TXNPI 1871672436

Payments from drug & device makers

$52,180in general payments, 2019–2025

Across 481 payments — averaging $108.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$34K
  • Pfizer$11K
  • AbbVie$1K
  • Novo Nordisk$714
  • Lilly USA, LLC$484
  • Merck$473
  • plus $4K from 54 others

What the payments were for

  • Food & beverage$7,471100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi US Services Inc.6$34,235
Pfizer58$10,946
AbbVie(2 entities)68$1,172
Novo Nordisk46$714
Lilly USA, LLC32$484
Merck15$473
GSK28$416
Amgen20$376
Amarin Pharma, Inc.16$334
Johnson & Johnson37$284
AstraZeneca19$280
Boehringer Ingelheim10$194
Bayer10$183
Biohaven Pharmaceutical Holding Company Ltd.7$170
Esperion Therapeutics, Inc.9$163
Sanofi Pasteur Inc.5$121
Dexcom, Inc.5$85
Novartis5$78
Abbott4$77
Astellas Pharma US Inc4$73
Exact Sciences4$66
Biohaven Pharmaceuticals, Inc.3$62
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC4$57
Phathom Pharmaceuticals, Inc.4$56
Eisai Inc.3$55
Axsome Therapeutics, Inc.3$52
Idorsia Pharmaceuticals US Inc3$51
Corcept Therapeutics2$47
Almatica Pharma LLC2$44
Teva Pharmaceuticals USA, Inc.2$43
E.r. Squibb & Sons, L.L.C.3$40
Bausch Health US, LLC3$40
Althera Pharmaceuticals LLC3$39
Ironshore Pharmaceuticals Inc.2$37
Sumitomo Pharma America, Inc.2$37
Sanofi-aventis U.S. LLC2$37
Alk-abello, Inc1$35
Corium, LLC1$32
Genentech USA, Inc.2$31
Seqirus USA Inc2$30
Supernus Pharmaceuticals, Inc.2$30
IBSA Pharma Inc.2$30
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$30
Shield Therapeutics Inc2$28
Nalpropion Pharmaceuticals LLC2$27
Boston Scientific1$26
Lundbeck LLC1$24
Dynavax Technologies Corporation2$23
Takeda Pharmaceuticals U.S.A., Inc.1$22
Nevro Corp.1$20
Medtronic1$20
Xeris Pharmaceuticals, Inc.1$19
RGH Enterprises LLC1$18
Vertical Pharmaceuticals, LLC1$17
Biogen1$16
Adlon Therapeutics L.p.1$15
Redhill Biopharma Inc.1$13
Shionogi Inc1$13
Vistapharm, Inc.1$12
Kowa Pharmaceuticals America, Inc.1$12

How this compares

$52,180 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$112,859
Medicare patients
427
Services billed
1,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol87$91,632
OzempicSemaglutide68$78,244
JardianceEmpagliflozin56$60,768
MounjaroTirzepatide42$46,450
JanuviaSitagliptin Phosphate43$46,222
EliquisApixaban39$35,047
XareltoRivaroxaban22$26,029
RybelsusSemaglutide17$25,688
TradjentaLinagliptin11$13,597
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$13,119
VascepaIcosapent Ethyl17$12,616
Breo ElliptaFluticasone/Vilanterol16$12,356
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine12$10,773
MyrbetriqMirabegron17$9,785
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$8,215

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$714$103,93285 claims
AstraZenecaFarxiga$280$91,63287 claims
Boehringer IngelheimJardiance, Tradjenta$194$74,36667 claims
Lilly USA, LLCMounjaro$484$46,45042 claims
MerckJanuvia$473$46,22243 claims
PfizerEliquis$10,946$35,04739 claims
Johnson & JohnsonXarelto$284$26,02922 claims
GSKBreo Ellipta$416$12,35616 claims
Astellas Pharma US IncMyrbetriq$73$9,78517 claims
AbbVieSynthroid$1,172$2,08642 claims
Sanofi-aventis U.S. LLCLantus$37$1,29317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →